US FDA clearance for MicroBlate™ Flex device

Thursday, January 07, 2021

Creo Medical Group plc, the medical device company focused on the emerging field of surgical endoscopy, announces that it has received 510(k) clearance from the US Food & Drug Administration ('FDA') for its tissue ablation device MicroBlate™ Flex.

MicroBlate™ Flex is the fourth device within Creo's portfolio of flexible endoscopy devices for the gastrointestinal ('GI') market to receive FDA regulatory clearance, alongside CE marking already received across the range in 2020. The first Creo product to receive FDA clearance, Speedboat™ Inject, is being used by clinicians in the UK, EU, US, South Africa and APAC.

Creo's suite of devices have been designed to be used with the CROMA Advanced Energy Platform, powered by Kamaptive™ full-spectrum adaptive technology, a seamless, intuitive integration of multi-modal energy sources, optimised to adapt to the tissue effect required for different procedures such as resection, dissection, coagulation and ablation.

About MicroBlate™ Flex
Creo's MicroBlate™ tissue ablation technology utilises Creo's very high frequency microwave energy allowing physicians to precisely ablate diseased tissue in multiple organ types and many different clinical access methods.  MicroBlate™ Flex is an additional soft tissue ablation device within the range, designed to ablate nodules and tumours in several soft tissue types, including the lung. MicroBlate™ Flex has potential to treat a number of other conditions, where a small diameter flexible device enables access into otherwise inaccessible regions of the body. MicroBlate™ Flex could be particularly useful to treat a range of ENT indications, including nasopharyngeal cancer and nasal polyps.

Creo's additional ablation product, MicroBlate™ Fine also received 510(k) clearance from the FDA in November 2020 and the first in-man clinical use of MicroBlate™ Fine was announced in December 2020. FDA clearance paves the way for the roll-out of these devices into the US market and with the full range of products CE marked during 2020 Creo also has access to the EU and UK markets enabling commercialisation of the GI suite.

Full details of Creo's product range can be found here:

Craig Gulliford, Chief Executive Officer of Creo, commented:

"We are delighted to receive FDA clearance for the MicroBlate™ Flex device and we remain focussed on completing our programme of regulatory clearances for the full suite of advanced energy surgery products for the flexible endoscopy market. We expect to see further first clinical use of our products in various markets and we look forward to utilising our enhanced global sales and marketing capability to drive commercialisation of our range."

Creo Medical Group plc
Richard Rees (CFO)
+44 (0)1291 606 005

Cenkos Securities plc
+44 (0)20 7397 8900
Stephen Keys / Camilla Hume (NOMAD)
Michael Johnson / Russell Kerr (Sales)

Walbrook PR Ltd
Tel: +44 (0)20 7933 8780 or
Paul McManus / Lianne Cawthorne
Mob: +44 (0)7980 541 893 / +44 (0)7515 909 238

About Creo Medical
Creo Medical, founded in 2003, is a medical device company focused on the development and commercialisation of minimally invasive surgical devices, by bringing advanced energy to endoscopy. The Company's mission is to improve patient outcomes by applying microwave and RF energy to surgical endoscopy. Creo has developed the CROMA Advanced Energy Platform powered by Kamaptive™ full-spectrum adaptive technology to optimise surgical capability and patient outcomes. Kamaptive™ is a seamless, intuitive integration of multi-modal energy sources, optimised to dynamically adapt to patient tissue during procedures such as resection, dissection, coagulation and ablation of tissue. Kamaptive™ technology provides clinicians with increased flexibility, precision and controlled surgical solutions.

The Company's strategy is to bring its CROMA Advanced Energy Platform powered by Kamaptive™ technology to market, enabling a wide range of medical devices which the Company has designed, initially for the emerging field of GI therapeutic endoscopy, an area with high unmet needs. The CROMA Advanced Energy Platform will be developed further for bronchoscopy and laparoscopy procedures. The Company believes its technology can impact the landscape of surgery and endoscopy by providing a safer, less-invasive and more cost-efficient option of treatment.

Latest Issue
Get instant
access to our latest e-book